rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Gain Therapeutics, Inc.

GANX · Nasdaq

Health CareBiotechnologyNot moving yet

GANX stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 31 weeks. It is 31.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 31
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
47 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders47+9 on the quarter
New · exited13 · 4
Reported value$14.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MARSHALL WACE, LLPadded · filed 13 Aug 20261,923,546$3.9M+153,758+8.7%
Potomac Capital Management, Inc.reduced · filed 14 Aug 2026946,400$1.9M-62,200−6.2%
JONES FINANCIAL COMPANIES LLLPreduced · filed 14 Aug 2026608,592$1.1M-23,023−3.6%
DME Capital Management, LPunchanged · filed 14 Aug 2026566,130$1.1M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026480,269$975K+80,383+20.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026453,501$921K+6,159+1.4%
BlackRock, Inc.added · filed 7 Aug 2026274,957$558K+49,911+22.2%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026231,534$470K+1,555+0.7%
UBS Group AGreduced · filed 13 Aug 2026215,012$436K-5,477−2.5%
Stratos Wealth Partners, LTD.added · filed 11 Aug 2026200,000$406K+68,379+52.0%
31 Mar 2023 – 30 Jun 2026
183246Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Claude Nicaise Company insiderDirector · last 15 Jul 20260 · 0
Dov A. Goldstein Company insiderDirector · last 15 Jul 20260 · 0
Gwen A. Melincoff Company insiderDirector · last 15 Jul 20260 · 0
Hans Peter Hasler Company insiderDirector · last 15 Jul 20260 · 0
Jeffrey Scott Riley Company insiderDirector · last 15 Jul 20261 · 0
Khalid Islam Company insiderDirector · last 15 Jul 20261 · 0
Gene Mack Company insiderCEO, President · last 24 Mar 20261 · 0
Gianluca Fuggetta Company insiderSee Remark · last 24 Mar 20260 · 0
Eric I. Richman Company insiderDirector · last 24 Jun 20255 · 0
Matthias Alder Company insiderChief Executive Officer · last 26 Mar 20240 · 2
Charles Evan Ballantyne Company insiderChief Financial Officer · last 10 Apr 20230 · 0
Salvatore Calabrese Company insiderChief Financial Officer · last 23 Mar 20232 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-96.1%
Debt to equityFY 2025 · to 31 Dec 20250.03×
Share count trendFY 2025 · to 28 Feb 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$20.8M

Analyst forecasts

No analyst forecasts yet.